Skip to main content

Table 1 Characteristics of included trials

From: Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis

Trial

Design

Time

Region

Primary

Treatment

Median follow-up

Sample

Median

Histology(%)

Consolidation

Radiotherapy

Radiotherapy

  

Range

 

Endpoint

 

(months)

Size

Age

(SCC/non-SCC)

Chemotherapy

Dose(Gy)

Technology

Liang/2017 [4]

III

2007–2011

China

OS

EP

73

95

59

68.4/31.6

50.5%

60–66

3D

    

PC

 

96

57

64.6/35.4

35.4%

  

Wang/2012 [5]

II

2004–2007

China

OS

EP

46

33

55.4

69.7/30.3

75.8%

60–66

3D

    

PC

 

32

60.9

62.5/37.5

59.4%

  

Shuayb/2018 [6]

II

NR

Bangladesh

NR

EP

NR

30

NR

NR

NR

45

NR

    

PC

 

30

NR

NR

NR

  

Bradley/2015 [7]

III

2007–2011

USA

OS

PC-Cet

21

237

64

43/57

67%

60–74

3D

    

PC

23

228

64

46/54

67%

  

Sugawara/2013 [8]

II

2006–2009

Japan

ORR

UP

20

35

62

42.9/57.1

60%

60

2D − +3D

    

NP

 

31

61

35.5/64.5

58.1%

  

Zhao/2016 [9]

III

2008–2012

China

OS

NP

29

48

57.4

67/33

88%

60.6–74.4

3D

    

PP

 

52

60.3

60/40

87%

  

Sasaki T/2018 [10]

II

2009–2012

Japan

OS

SP

NR

54

60

31.5/68.5

59.3%

60

3D

    

NP

 

54

62

31.5/68.5

44.4%

  

Curran Jr./2011 [11]

III

1994–1998

USA

OS

NP

132

195

60

38/62

NR

60

NR

    

EP

 

187

63

37/63

NR

  

Oh/2013 [12]

III

2005–2007

Korea

ORR

PC

Over 36

33

64

72.7/27.3

63.6%

60–66

3D

    

DP

 

29

61.5

69/31

65.5%

  
    

GP

 

31

64

64.5/35.5

64.5%

  

Segawa/2010 [13]

III

2000–2005

Japan

OS

MVP

NR

101

NR

52.5/37.5

NR

60

2D

    

DP

 

99

NR

44.4/55.6

NR

  

Takiguchi/2018 [14]

II

2011–2014

Japan

OS

SP

48

53

NR

26.4/73.6

NR

60

NR

    

DP

 

53

NR

20.8/79.2

NR

  

Yamamoto/2010 [15]

III

2001–2005

Japan

OS

MVP

NR

146

63

47.9/52.1

41%

60

2D

    

IC

 

147

62

42.2/57.8

29.3%

  
    

PC

 

147

63

48.3/51.7

49.7%

  

Senan/2016 [16]

III

2008–2012

USA

OS

PP

22

301

59.5

100

76%

60–66

3D

    

EP

23

297

58.7

100

74.3%

  

Govindan/2011 [17]

II

2005–2008

USA

OS

PP

32

48

65

35/65

69.8%

70

3D

    

PP-Cet

 

53

66

34/66

85.4%

  
  1. Abbreviations:OS overall survival, ORR overall response rate, SP S-1-cisplatin, UP UFT-cisplatin, NP vinorelbine-cisplatin, EP etoposide-cisplatin, MVP mitomycin-vindesine-cisplatin, DP docetaxel-cisplatin, PC paclitaxel-cisplatin/carboplatin, PP pemtrexed-cisplatin/carboplatin, IC irinotecan-carboplatin, GP gemcitabine-cisplatin, Cet cetuximab, SCC squamous cell carcinoma, 2D two-dimensional radiotherapy, 3D three-dimensional conformal radiotherapy, NR not reported